Trial Profile
Hexaminolevulinate (Cysview) improves the detection of non-muscle invasive bladder cancer by using Blue Light Cystoscopy: A prospective multicenter registry study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2018
Price :
$35
*
At a glance
- Drugs Hexyl aminolevulinate (Primary)
- Indications Bladder cancer
- Focus Diagnostic use
- 12 Jul 2018 New trial record